

10 Rec'd PCT/TC

10/506715  
PCT/EP-03/02204  
07 SEP 2004



REC'D 22 APR 2003

WIPO PCT

Patents Office  
Government Buildings  
Hebron Road  
Kilkenny

I HEREBY CERTIFY that annexed hereto is a true copy of the documents filed in connection with the following patent application:


Application No. 2002/0184

Date of Filing 7th March 2002

Applicant Eurand Pharmaceutical Limited, an Irish Company  
of Harcourt Centre, Harcourt Street, Dublin 2,  
Ireland

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1 (a) OR (b)

Dated this 18<sup>th</sup> day of December 2002.



*Brian M. Keenan*

An officer authorised by the  
Controller of Patents, Designs and Trademarks.

**Best Available Copy**

020184

FORM NO. 1

APPLICATION No. \_\_\_\_\_

**REQUEST FOR THE GRANT OF A PATENT  
PATENTS ACT, 1992**

The Applicant named herein hereby request

- ☒ the grant of a patent under Part II of the Act  
☐ the grant of a short-term patent under Part III of the Act

on the basis of the information furnished hereunder.

**1. APPLICANT**

Name

EURAND PHARMACEUTICALS LTD

Address

Harcourt Centre, Harcourt Street, Dublin 2, Ireland

Description/Nationality

An Irish Company

**2. TITLE OF INVENTION**

"Process for loading and thermodynamically activating drugs on polymers by means of superficial fluids"

**3. DECLARATION OF PRIORITY ON BASIS OF PREVIOUSLY FILED  
APPLICATION FOR SAME INVENTION (SECTIONS 25 & 26)**

Previous filing date

Country in or for  
which filed

Filing No.

**4. IDENTIFICATION OF INVENTOR(S)**

Name(s) of person(s) believed by Applicant(s) to be the inventor(s)

1. BRESCIANI, Massimo
2. DOBETTI, Luca
3. KIRCHMAYER, Stefano

Address

1. Via delle Campanelle, 170-34100 Trieste Italy.
2. Via Vaglieri 9/3-34100 Trieste Italy
3. Via dei Caldana, 10-34100 Trieste, Italy

5. **STATEMENT OF RIGHT TO BE GRANTED A PATENT (SECTION 17(2)(B))**

By virtue of a contract of employment.

6. **ITEMS ACCOMPANYING THIS REQUEST - TICK AS APPROPRIATE**

- (i) ☒ prescribed filing fee (€125.00)
- (ii) ☒ specification containing a description and claims
- ☐ specification containing a description only
- ☐ Drawings referred to in description or claims
- (iii) ☒ An abstract
- (iv) ☐ Copy of previous application(s) whose priority is claimed
- (v) ☐ Translation of previous application whose priority is claimed
- (vi) ☒ Authorisation of Agent (this may be given at 8 below if this Request is signed by the Applicant(s))

7. **DIVISIONAL APPLICATION**

The following information is applicable to the present application which is made under Section

24 -

Earlier Application No:

Filing Date:

8. **AGENT**

The following is authorised to act as agent in all proceedings connected with the obtaining of a Patent to which this request relates and in relation to any patent granted -

**Name**

F. R. KELLY & CO.

**Address**

at their address as recorded for the time being in the Register of Patent Agents

9. **ADDRESS FOR SERVICE (IF DIFFERENT FROM THAT AT 8)**

**EURAND PHARMACEUTICALS, LTD**  
F. R. KELLY & CO.

By:

  
EXECUTIVE

TRUE COPY  
AS  
LODGED

APPLICATION No.

020184

1

# PROCESS FOR LOADING AND THERMODYNAMICALLY ACTIVATING DRUGS ON POLYMERS BY MEANS OF SUPERCRITICAL FLUIDS

## Field of the invention

The present invention refers to a process by means of the supercritical fluids for  
5 loading and thermodynamically activating drugs on inert polymers.

## Prior art

The technology with supercritical fluids has been developed owing to the particular  
properties of these fluids for a safer use of them in pharmaceutical field compared  
to the use of organic solvents.

10 A supercritical fluid is a material above its temperature and pressure conditions; it  
exhibits interesting behaviour by combining the properties of conventional liquids  
and gases. Although their gas-like low viscosities lead to higher rates of flow and  
diffusion, their liquid-like densities permit higher solvent power. For a detailed  
description of supercritical fluids, reference can be made to e.g. *Kirk-Othmer*,  
5 *Encyclopedia of Chemical Technology*, vol.23, p.452-453.

The use of supercritical fluids could be, in principle, a valid alternative to the use  
of solvents in pharmaceutical field. In fact, the supercritical fluids, which are gases  
in standard environmental conditions, are completely removed from the  
compounds at the end of the process.

20 The supercritical fluids are extendedly used to reduce the particle size of drugs  
and to produce solid particles having a narrow size distribution. This can also be  
made at mild operating conditions, avoiding the stresses given by other more  
common techniques (i.e. milling, micronisation). As an example, WO 97/14407 (I.  
B. Henriksen et al.) deals with the preparation of water-insoluble drugs having an

average size from 100 to 300 nm, obtained by dissolving them in a solution and then spraying the solution into supercritical fluid in presence of suitable surface modifiers.

In the last year, the technology with supercritical fluids has been used for loading

5 organic molecules in polymers. M. L. Sand (US Patent 4,598,006) discloses a method for impregnating thermoplastic polymers with additives such as fragrances, pest control agents and pharmaceutical compounds. F. Carli et al. (WO 99/25322) describes the loading of cross-linked polymers with drugs dissolved in supercritical fluids.

10 Oral delivery of poorly soluble drug has become, in the last years, one of the most challenging problems for advanced pharmaceutical research. This in turn leads to formulations with high drug content which often must be delivered repeatedly to obtain and maintain therapeutic plasma levels.

A way to enhance the solubility of poorly soluble or insoluble drugs is to 5 thermodynamically activate them by forming an amorphous phase and/or nanocrystalline structures from the original crystalline state. This results in drug solubilisation kinetic, having dissolution rate and supersaturation concentrations, that is much higher than that obtainable with differently formulated drug in crystalline state. As a consequence, a strong increase of the drug effects "in-vivo" 20 is allowed by enhancing the bioavailability, reducing the onset of action ( $t_{max}$ ) and decreasing the variability between subjects.

The process described in WO 99/25322 has then been applied to check the suitability of supercritical fluids for the thermodynamic activation of drugs in cross-linked polymers. Positive results in terms of drug activation have been obtained.

Now, we have surprisingly found that a pre-treatment of the cross-linked polymer with pure supercritical fluid allows a higher degree and a more rapid kinetic of drug loading into cross-linked polymers (shorter process time) when compared to a standard process without pre-treatment. Moreover, a higher thermodynamic activation of the drugs is also obtained by means of a pre-treatment step.

### **Summary of the invention**

The present invention refer to a process of loading drugs in a thermodynamic activated form into polymers by means of supercritical fluids. The process includes a pre-treatment step of the cross-linked polymer with pure supercritical fluid to allow a higher degree and a more rapid kinetic of drug loading into cross-linked polymers and also a higher thermodynamic activation of the drugs.

### **Detailed description of the invention**

Object of the present invention is a process to load drugs into cross-linked polymers by means of supercritical fluids. The process includes a pre-treatment step of a cross-linked polymer with a supercritical fluid; this process allows to obtain a higher degree and a more rapid kinetic of drug loading into cross-linked polymers (shorter process time) and also a higher thermodynamic activation of the drugs.

The supercritical fluid used in the pre-treatment step is free from any drugs (hereinafter referred as "pure supercritical fluid"); the pure supercritical fluid as such can be produced by means known in the art, i.e. by compressing the fluid and passing it through a heat exchanger in order to bring it beyond those temperature and pressure values at which it forms a supercritical fluid. Non limiting examples of substances from which supercritical fluids can be obtained

are carbon dioxide, hydrocarbon (ethylene, propylene), chlorofluorocarbon, nitrous oxide; supercritical fluids can be used alone or as a mixture of more of them.

In the pre-treatment step, the pure supercritical fluid is pumped into a reactor containing the pure cross-linked polymer (i.e. the polymer not containing any

5 drugs) and is maintained in supercritical conditions of temperature and pressure;

the contact time between pure supercritical fluid and pure polymer is preferably between 1 minutes and 6 hours, most preferably between 5 minutes and 4 hours.

The thus pre-treated polymer can be discharged from the reactor (after removing the supercritical fluid) and preserved for later loading with a drug, or can be

10 immediately loaded with the drug. In both cases, the drug-loading step can be effected by contacting the polymer with an aliquot of supercritical fluid containing

the drug dissolved therein (this solution can be formed e.g. by passing a supercritical fluid through an extractor containing the drug to be solubilised) and

pumping this solution into the reactor containing the cross-linked polymer,

5 maintained in suitable supercritical conditions of temperature and pressure. The

contact time of the supercritical fluid containing the solubilised drug with the polymer is preferably between 2 minutes and 48 hours, most preferably between

10 minutes and 12 hours.

The contact between polymer and fluid, for both pre-treatment and drug-loading

20 step, can be carried out in static or dynamic conditions or in a combination of them. In the static case, a predetermined volume of supercritical fluid, with (drug-

loading step) or without (pre-treatment step) the solubilised drug, is introduced in a

container and allowed to equilibrate in contact with the polymer. In the dynamic

process, the stream of supercritical fluid, generated by the pump at the outlet of

the extractor, is passed through a column containing the polymer. The combined process, static plus dynamic, can be obtained, for example, by passing dynamically a volume of supercritical fluid without the solubilised drug, through a column, by stopping the stream, leaving the supercritical fluid in contact with polymer in static conditions, and then passing again the supercritical fluid with the solubilised drug through the column, and leaving the supercritical fluid in contact with polymer in static conditions.

During both pre-treatment and drug-loading steps, pressure and temperature are maintained controlled, preferably constant, so as to maintain the fluid inside the reactor in supercritical conditions: this can be done by suitably using heat exchangers, constant monitoring of the pressure, and releasing controlled amounts of supercritical fluid when fresh fluid is added into the reactor.

At the outlet of the reactor, the fluid stream is passed through an absorber suitable to remove from the stream any traces of the residual drug. The fluid stream is then brought back to the ambient conditions and drained or, if necessary, cooled, sent to a reflux receiver and recycled.

The addition of the drug-loaded supercritical fluid results with the polymer structure being filled with the a supercritical solution of the drug. After the drug-loading phase, the supercritical fluid is removed from the reactor, causing the dissolved drug to precipitate in microparticle form inside the cross-linked polymeric network; the removal of the supercritical fluid can be conveniently effected by decreasing the pressure (and/or increasing the temperature) inside the reactor, thereby allowing the fluid to evaporate in gaseous form; when the concentration of drug increases over the solubility value in the fluid, the drug starts precipitating



into the polymeric network; the total removal of the fluid leaves a solid powder in the reactor consisting of the drug-loaded polymer.

Cross-linked polymers useful for the present invention are any polymers (hydrophilic, hydrophobic or amphiphilic), whose polymeric chains are cross-linked

5 by interchain bonds: these bonds can be naturally present in the polymer as such,

or can be added by performing ad-hoc cross-linking reactions. As known in the art,

cross-linking can be obtained by polymerisation processes that produces

physically crosslinked polymers, or by a chemical reaction of linear polymers with

crosslinking agents. Not exhaustive examples of cross-linked polymer useful for

10 the present invention are: cross-linked polyvinylpyrrolidone, cross-linked cellulose

derivatives such as sodium croscarmellose, starch and its derivatives such as

sodium starch glycolate, cyclodextrins and their derivatives, cross-linked

polystyrene and cross-linked acrylic polymers. Cross-linked polymers can be used

alone or as a mixture of more of them.

5 The cross-linked polymer loaded with this process contains preferably from 0.5%

to 70%, more preferably from 3% to 50%, by weight of the active drug to the final

total mass (cross-linked polymer + loaded drug).

Any drugs which can be solubilised into the supercritical fluid can be used for the purpose of the present invention. Among the drugs which can be loaded and

20 activated according to the process of the invention, not exhaustive examples are

Cox-2 inhibitors, anti-inflammatory drugs such as nimesulide, piroxicam,

naproxene, ketoprofen, ibuprofen and diacerhein, anti-fungal drugs such as

griseofulvin, itraconazole, fluconazole, miconazole and ketoconazole,

bronchodilators/anti-asthmatic drugs such as zafirlukast, salbutamol,

beclomethasone, flunisolide, clenbuterol, salmeterol and budesonide, steroids  
 such as estradiol, estriol, progesterone, megestrol acetate and  
 medroxyprogesterone acetate, anti-hypertensive/anti-thrombotic/vasodilator drugs  
 such as nifedipine, nicergoline, nicardipine, lisinopril, enalapril, nicorandil,  
 5 celiprolol and verapamil, benzodiazepines such as temazepam, diazepam,  
 lorazepam, fludiazepam, medazepam and oxazolam, anti-migraine drugs such as  
 zolmitriptan and sumatriptan, anti-hyperlipoproteinemic drugs such as fenofibrate,  
 lovastatin, atorvastatin, fluvastatin and simvastatin, anti-viral/anti-bacterial drugs  
 such as tosufloxacin, ciprofloxacin, ritonavir, saquinavir, nelfinavir, acyclovir and  
 10 indinavir, immunodepressant drugs such as tacrolimus, rapamycin and didanisine,  
 anti-histaminic drugs such as loratidine, anti-thumoral drugs such as etoposide,  
 bicalutamide, tamoxifen, doclitaxel and paclitaxel, anty-psycotic drugs such as  
 risperidone, anti-osteoporotic drugs such as raloxifene, anti-convulsant such as  
 carbamazepine, analgesic/narcotic drugs such as oxycodone, hydrocodone,  
 15 morphine and butorpanol, muscle relaxant such as tinazadine, anti-convulsant  
 drug such as phenytoin, anti-ulcerative drugs such as famotidine.

The present inventors have found that when a cross-linked polymer is treated with  
 a supercritical fluid according to the pre-treatment described above, it can be  
 loaded with much higher amounts of drug than in the case of the untreated  
 20 polymer: it is believed that the pre-treatment with the supercritical fluid (not  
 containing any drugs) operates a chemical-physical modification in the polymer  
 network, making it more prone to capture the drug particles in a subsequent drug-  
 loading process: this fact is confirmed in the experimental part, where it is shown  
 that a drug loading process by means of supercritical fluids results in a

significantly higher percentage of drug incorporation if, in place of a common cross-linked polymer, the cross-linked polymer pre-treated in accordance with the pre-treatment of the invention is used.

In accordance with the above findings, the present invention also embraces a

5 method to increase the drug-loading capacity of a cross-linked polymer,

~~characterised by treating said cross-linked polymer with a supercritical fluid not~~

containing any drugs. A further consequent object of the invention is a modified cross-linked polymer, having an enhanced capacity to incorporate drugs, obtained by treating a cross-linked polymer with a supercritical fluid not containing any  
10 drugs, in the modalities hereabove described.

A further surprising finding is that the drug incorporated in the polymer according to the present process shows an increased amount in its highly bioavailable amorphous and nanocrystalline fractions. The increase in the amorphous/nanocrystalline fraction obtains an increased bioavailability of the drug,  
15 due to the much quicker solubility of these forms with respect to the crystalline one.

In accordance with the above findings, the invention also comprises a method to increase the amorphous/nanocrystalline fraction of a drug (or to reduce its crystalline fraction and thereby increasing its activation degree), characterised by:

20 (a) pre-treating a cross-linked polymer with a supercritical fluid; (b) contacting said pre-treated polymer with a supercritical fluid containing the drug dissolved therein; (c) removing the supercritical fluid, which results in the drug being precipitated inside the cross-linked polymer in an increased amorphous/nanocrystalline fraction.

The process of the invention allows for the first time to incorporate large amounts of drugs into cross-linked polymers while, at the same time increasing substantially the bioavailability of the incorporated drug. Consequently, new highly potent pharmaceutical compositions can be obtained, associating a high drug content with an enhanced bioavailability of the same. These pharmaceutical compositions are also within the scope of the present invention.

The invention is further illustrated with reference to the following non-limitative examples.

## EXPERIMENTALS

10 The presence of amorphous, nanocrystalline or crystal phase can be detected by means of Differential Scanning Calorimetry (DSC). Compared to the sharp melting peak of the drug crystal, the nanocrystals present a broader peak with a markedly lower maximum of temperature (I. Colombo et al. *4<sup>th</sup> Int. Conf. Pharm. Technol.*, 1986; F. Carli et al. *Acta Pharm. Jugosl.* **38**, 361, 1988). The amorphous phase  
15 does not show any thermal event.

In the examples, the activation level is expressed as the fraction of crystalline form. It is determined by comparing the enthalpy relative to the melting of the crystals in the polymer ( $\Delta H_{\text{melting}}$ ) to that of pure drug ( $\Delta H_0$ ). The  $\Delta H_{\text{melting}}/\Delta H_0$  ratio, normalized in accordance with the drug assayed in the polymer, is then  
20 considered equal to the fraction of crystalline form. The higher the amount of crystals (higher crystallinity), the lower the thermodynamic activation level of the drug.

### Example 1

Reference (1R)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are contacted for 8 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO<sub>2</sub>) saturated with nimesulide. Temperature and pressure are 40°C and 130 bar, respectively.

## 5 Invention (1I)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are pre-treated for 30 minutes with a 450 mL/min stream of supercritical in carbon dioxide (CO<sub>2</sub>). The cross-linked polymer is then contacted for 6 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO<sub>2</sub>) saturated with nimesulide. Temperature and pressure of both pre-treatment and loading steps are 40°C and 130 bar, respectively.

The results, reported in Table 1, show a higher degree of drug loading, a shorter process time (even considering the pre-treatment step) and a higher activation level (lower crystallinity) in the example 1I of the invention compared to the reference 1R of prior art.

**Table 1.**

	Drug content (%)	T <sub>melting</sub> (°C)	ΔH <sub>melting</sub> (J/g)	Crystallinity (%)
Nimesulide	-	148.4	109.2	100
1R	8.2	147.9	1.5	17
1I	9.1	no peak	-	0

## Example 2

### Reference (2R)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are contacted for 8 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO<sub>2</sub>) saturated with ibuprofen. Temperature and pressure are 40°C and 130 bar, respectively.

#### 5 Invention (2I)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are pre-treated for 30 minutes with a 450 mL/min stream of supercritical in carbon dioxide (CO<sub>2</sub>). The cross-linked polymer is then contacted for 6 hours with a 450 mL/min stream of supercritical in carbon dioxide (CO<sub>2</sub>) saturated with ibuprofen. Temperature and pressure of both pre-treatment and loading steps are 40°C and 130 bar, respectively.

The results, reported in Table 2, show a higher degree of drug loading, a shorter process time (even considering the pre-treatment step) and a higher activation level (lower crystallinity) in the example 2I of the invention compared to the reference 2R of prior art.

**Table 2.**

	Drug content (%)	T <sub>melting</sub> (°C)	ΔH <sub>melting</sub> (J/g)	Crystallinity (%)
Ibuprofen	-	75.1	122.9	100
1R	10.5	74.4	4.4	34
1I	16.0	no peak	-	0

#### Example 3

### Reference (3R)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are contacted for 8 hours with a 450 mL/min stream of supercritical in ethylene saturated with ibuprofen. Temperature and pressure are 30°C and 120 bar, respectively.

### Invention (3I)

5 g of cross-linked polyvinylpyrrolidone, placed in a cylindrical reactor of 50 cm length and 0.6 cm diameter, are pre-treated for 30 minutes with a 450 mL/min stream of supercritical in ethylene. The cross-linked polymer is then contacted for 6 hours with a 450 mL/min stream of supercritical in ethylene saturated with ibuprofen. Temperature and pressure of both pre-treatment and loading steps are 40°C and 130 bar, respectively.

The results, reported in Table 3, show a higher degree of drug loading, a shorter process time (even considering the pre-treatment step) and a higher activation level (lower crystallinity) in the example 3I of the invention compared to the reference 3R of prior art.

**Table 3.**

	Drug content (%)	T <sub>melting</sub> (°C)	ΔH <sub>melting</sub> (J/g)	Crystallinity (%)
Ibuprofen	-	75.1	122.9	100
1R	6.4	74.0	7.2	92
1I	7.9	74.2	2.3	24

## CLAIMS

1. A process to load a drug into a cross-linked polymer, comprising the following steps:

a. pre-treating said cross-linked polymer with a supercritical fluid;

b. contacting said pre-treated cross-linked polymer with a supercritical fluid containing the drug dissolved therein;

c. removing the supercritical fluid, thereby causing the drug to precipitate inside the cross-linked polymer.

2. Process according to claim 1, wherein in step a. , the cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 1 minute and 6 hours.

3. Process according to claims 1-2, wherein in step a. , the cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 5 minutes and 4 hours.

4. Process according to claims 1-3, wherein in step b. , the pre-treated cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 2 minutes and 48 hours.

5. Process according to claims 1-4, wherein in step b. , the pre-treated cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 10 minutes and 12 hours.

6. Process according to claims 1-5, wherein the contact of the cross-linked polymer with the supercritical fluid is effected in static and/or dynamic conditions.



7. Process according to claims 1-6, wherein said supercritical fluid is chosen among carbon dioxide, ethylene, propylene, chlorofluorocarbon, nitrous oxide, and mixtures thereof.
8. Process according to claims 1-7, wherein said cross-linked polymer is chosen  
5 among cross-linked polyvinylpyrrolidone, cross-linked cellulose derivatives, starch and its derivatives, cyclodextrins and their derivatives, cross-linked polystyrene, cross-linked acrylic polymers, and mixtures thereof.
9. Process according to claims 1-8, further characterised in that the thus loaded  
10 drug is present in the cross-linked polymer in high amorphous and nanocrystalline fraction.
10. A method to increase the drug-loading capacity of a cross-linked polymer, consisting in treating said cross-linked polymer with a supercritical fluid not containing any drugs.
11. Method according to claim 10, wherein the cross-linked polymer is maintained  
5 in contact with the supercritical fluid for a time comprised between 1 minute and 6 hours.
12. Method according to claims 10-11, wherein the cross-linked polymer is maintained in contact with the supercritical fluid for a time comprised between 5 minutes and 4 hours.
- 20 13. Method according to claims 10-12, wherein the contact of the polymer with the supercritical fluid is effected in static and/or dynamic conditions.
14. Method according to claims 10-13, wherein the supercritical fluid is chosen among carbon dioxide, ethylene, propylene, chlorofluorocarbon, nitrous oxide, and mixtures thereof.

15. Method according to claims 10-14, wherein the cross-linked polymer is chosen among cross-linked polyvinylpyrrolidone, cross-linked cellulose derivatives, starch and its derivatives, cyclodextrins and their derivatives, cross-linked polystyrene, cross-linked acrylic polymers, and mixtures thereof.

5 16. Modified cross-linked polymer, having enhanced drug-loading properties, obtainable by treating a cross-linked polymer with a supercritical fluid not containing any drugs.

10 17. Modified cross-linked polymer according to claim 16, obtainable by treating the cross-linked polymer with the supercritical fluid for a time comprised between 1 minute and 6 hours.

18. Modified cross-linked polymer according to claims 16-17, obtainable by treating the cross-linked polymer with the supercritical fluid for a time comprised between 5 minutes and 4 hours.

5 19. Modified cross-linked polymer according to claims 16-18, wherein the supercritical fluid is chosen among carbon dioxide, ethylene, propylene, chlorofluorocarbon, nitrous oxide, and mixtures thereof.

20 20. Modified cross-linked polymer according to claims 16-19, wherein the cross-linked polymer to be modified is chosen among cross-linked polyvinylpyrrolidone, cross-linked cellulose derivatives, starch and its derivatives, cyclodextrins and their derivatives, cross-linked polystyrene, cross-linked acrylic polymers, and mixtures thereof.

21. Modified cross-linked polymer according to claims 16-20, loaded with a drug.

22. Pharmaceutical composition containing the modified cross-linked polymer described in claim 21.

PROCESS FOR LOADING AND THERMODYNAMICALLY ACTIVATING DRUGS  
ON POLYMERS BY MEANS OF SUPERCRITICAL FLUIDS

**ABSTRACT**

The present invention refers to a process of loading drugs in a thermodynamic  
5 activated form into polymers by means of supercritical fluids. The process includes  
~~a pre-treatment step of the cross-linked polymer with pure supercritical fluid to~~  
allow a higher degree and a more rapid kinetic of drug loading into cross-linked  
polymers and also a higher thermodynamic activation of the drugs.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**